PharmAbcine Inc.

PharmAbcine's clinical asset, olinvacimab (TTAC-0001) is an anti-VEGFR2 neutralizing fully human IgG1. It is currently in three clinical trials:
1) Phase 2a in rGBM patients who progressed on bevacizumab.
2) Phase 1b combo trial with pembrolizumab in rGBM.
3) Phase 1b combo trial with pembrolizumab in mTNBC patients.
Olinvacimab has shown safety and efficacy as mono- and as combo treatment with pembrolizumab in clinical studies. It received ODD to treat rGBM from Korean MFDS and US FDA.

Potentially first-in-class preclinical candidates that we aim to initiate phase 1 clinical studies in 2022:
- PMC-309 (anti-VISTA) shows high selectivity for VISTA-expressing myeloid lineage cells including MDSCs and TAMs in TME. It induces anti-tumor effects by activating T cells and improving the delivery of TILs into TME. It shows synergistic anti-tumor activity with an anti-PD1 drug.
- PMC-403 (TIE2 activator) stabilizes leaky blood vessels and is being developed to treat indications including solid tumors, neovascular eye diseases, lung and kidney diseases.

Fee-for-service or collaboration-based Ab Discovery and Panning:
PharmAbcine has its own HuPhage library and innovative selection system. Our advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. We provide Ab discovery and development services using these cutting-edge technology platforms.... More Info Less Info